Piramal Pharma Limited Schedules Q4 & FY26 Earnings Conference Call for April 29
Piramal Pharma Limited will host a conference call on April 29, 2026, to discuss its Q4 and full-year FY2026 results. The call is scheduled from 9:30 AM to 10:15 AM IST. Dial-in details for international participants are also available.
This is a standard procedural announcement regarding an upcoming earnings call, which does not contain new material information about the company's performance or future outlook.
The announcement is a routine intimation of a conference call to discuss financial results, with no new financial or business performance data provided in this specific communication.
Piramal Pharma Limited (PPL) has announced an upcoming conference call for investors and analysts to discuss its financial results for the fourth quarter and the full fiscal year 2026. The call is scheduled to take place on April 29, 2026, from 9:30 AM to 10:15 AM IST.
PPL, a company with a diverse portfolio of products and services distributed across over 100 countries through its global development and manufacturing facilities, will provide insights into its performance. The company's business segments include Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and Piramal Consumer Healthcare. Additionally, PPL has strategic investments in Abbvie Therapeutics India Private Limited and Yapan Bio Private Limited.
Detailed dial-in information for various regions, including India, USA, UK, Singapore, and Hong Kong, has been provided, along with an option for express joining via Diamond Pass™ for prior registration.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.